ISARIC (International Severe Acute Respiratory and Emerging Infections Consortium)

A global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases

COVID-19 Report: 13 July 2020

Summary

The results in this report have been produced using data from the ISARIC COVID-19 database. For information, or to contribute to the collaboration, please contact ncov@isaric.org.

We thank all of the data contributors for collecting standardised data during these extraordinary times. We plan to issue this report of aggregate data regularly for the duration of the SARS-CoV-2/COVID-19 pandemic.

Please note the following caveats. This is a dynamic report which captures new variables and information as our understanding of COVID-19 evolves. Please observe the N of each result to note newly added variables with fewer data points. Information is incomplete for the many patients who are still being treated. Furthermore, it is likely that that we received more cases of severely ill individuals than those with relatively less severe illness; outcomes from these data, such as the proportion dying, must therefore not be used to infer outcomes for the entire population of people who might become infected. Some patients may be participants in clinical trials of experimental interventions. Many of the included cases are from the United Kingdom. Additional caveats are provided in the in the 'Caveats' section below.

Up to the date of this report, data have been entered for **85973** individuals from **545** sites across **42** countries.

The analysis detailed in this report only includes individuals:

1. for whom data collection commenced on or before 29 June 2020. (We have applied a 14-day rule to focus analysis on individuals who are more likely to have a recorded outcome. By excluding patients enrolled during the last 14 days, we aim to reduce the number of incomplete data records and thus improve the generalisability of the results and the accuracy of the outcomes. However, this limits our focus to a restricted cohort despite the much larger volumes of data held in the database.)

AND

2. who have laboratory-confirmed or clinically-diagnosed SARS-COV-2 infection.

The cohort satisfying the above criteria has 60430 cases (97.6% are laboratory-confirmed for SARS-COV-2 infection).

The flow chart in Figure 1 gives an overview of the cohort and outcomes as of 13 July 2020.

Demographics and presenting features

Of these 60430 cases, 34422 are males and 25899 are females – sex is unreported for 109 cases. The minimum and maximum observed ages were 0 and 106 years respectively. The median age is 73 years.

The observed mean number of days from (first) symptom onset to hospital admission was 7.6, with a standard deviation (SD) of 6.1 days and a median of 4 days. For all time-to-event variables, values greater than 120 days were treated as outliers and were excluded prior to any analysis.

The observed mean duration for the number of days from hospital admission to outcome (death or discharge) was 11.8, with SD 11.7 days and a median of 8 days. These estimates are based on all cases which have complete records on length of hospital stay (N = 55769).

The symptoms on admission represent the policy for hospital admission and containment at that time plus, whatever the case definition was. As time passes for most countries these will change. The five most common symptoms at admission were history of fever, shortness of breath, cough, fatigue/malaise, and confusion. Frequencies of symptom prevalence vary with age.

Outcomes

Outcomes have been recorded for 51270 patients, consisting of 34239 recoveries and 17031 deaths. Follow-up is ongoing for 3209 patients. Outcome records are unavailable for 5969 patients.

ICU/HDU: A total of 9754 (16%) patients were admitted at some point of their illness into an intensive care unit (ICU) or high dependency unit (HDU). Of these, 3348 died, 705 are still in hospital and 4335 have recovered and been discharged.

The observed mean and median durations (in days) from hospital admission to ICU/HDU admission were 2.9 and 1 respectively (SD: 6.4) – estimated from records on cases with complete date records on hospital admission and ICU/HDU entry (N = 8855).

The duration of stay in ICU/HDU had a mean of 12 days and a median of 8 (SD: 11.8 days) – estimated on only those cases with complete records for ICU/HDU duration or ICU/HDU start/end dates (N = 7891). Of these 9754 patients who were admitted into ICU/HDU, 3348 died, 705 are still in hospital and 4335 have recovered and been discharged. Outcome records are unavailable for 1366 cases. Approximately 38% of patients with complete records on ICU admission dates were admitted to ICU within the first day of hospital admission. The distribution of the number of days from admission to ICU admission is shown in Figure 11.

Treatment

Antibiotics were received by 45318/54510 (83.1%) patients, and 4552/53594 (8.5%) received antivirals. These treatment categories are not mutually exclusive since some patients received multiple treatments. (The denominators differ due to data completeness.) 39525/59095 (66.9%) patients received some degree of oxygen supplementation: of these, 9118/39525 (23.1%) received NIV and 5643/39525 (14.3%) IMV.

Of the patients admitted into ICU/HDU, 8119/8743 (92.9%) received antibiotics and 6671/13342 (50%) antivirals. 8944/9621 (93%) received some degree of oxygen supplementation, of which, 5070/8944 (56.7%) received NIV and 5375/8944 (60.1%) IMV.

A total of 9118 patients received non-invasive mechanical ventilation (NIV). The mean and median durations from admission to receiving NIV were 4.2 days and 2 days respectively (SD: 8.8 days) – estimated from records on cases with complete records on dates of hospital admission and NIV onset (N = 6983). The mean and median durations for NIV were 2.3 days and 0 days respectively (SD: 4.8 days) – estimated based on only those cases which have complete NIV duration records (N = 4097).

A total of 5643 patients received invasive mechanical ventilation (IMV). The mean and median durations from admission to receiving IMV were 3.8 days and 2 days respectively (SD: 7 days) – estimated from records on cases with complete records on dates of hospital admission and IMV onset (N = 4774). The mean, median and SD for the duration of IMV – estimated based on all 4145 cases with complete records on IMV stays – were 13.7 days, 11 days and 10.9 days respectively.

Corticosteroids have been used by 8758 / 53166 (16.5%) patients. This includes 1725 / 4896 (35.2%) of those who received IMV, 5410 / 31975 (16.9%) of those who had oxygen therapy but not IMV, and 1615 / 16237 (9.9%) of those who had no oxygen therapy. On 16 June, results for dexamethasone were released for the RECOVERY ransomized controlled trial (RECOVERY, 2020; RECOVERY Collaborative Group, 2020). This trial found that dexamethasone reduced deaths for patients receiving IMV and oxygen therapy, but not among patients not receiving respiratory support. Of patients admitted since 16 June, corticosteroids were received by 6 / 16 (37.5%) of those who received IMV, 53 / 147 (36.1%) of those who had oxygen therapy but not IMV, and 26 / 173 (15.0%) of those who had no oxygen therapy.

Figure 1: Overview of cohort and outcomes as of 13 July 2020.



Patient Characteristics

Figure 2: Age and sex distribution of patients. Bar fills are outcome (death/discharge/ongoing care) at the time of report.



Figure 3: **Top**: Frequency of symptoms seen at admission amongst COVID-19 patients. Bars are annotated with a fraction representing the number of patients presenting with this symptom over the number of patients for whom presence or absence of this symptom was recorded. **Middle**: The distribution of combinations of the four most common symptoms, amongst all patients for whom these data were recorded. Filled and empty circles below the x-axis indicate the presence or absence of each comorbidity. The "Any other" category contains all remaining symptoms in the top plot. **Bottom**: Heatmap for correlation between symptoms. Fill colour is the phi correlation coefficient for each pair of symptoms, calculated amongst patients with recorded presence or absence of both.




Proportion of patients
0.10
0.05
0.00
Any other
History of fever
Shortness of breath
Fatigue / Malaise
Cough (no sputum)
Symptoms present at admission


Altered consciousness / confusion
Seizures
Skin rash
Skin ulcers
Bleeding
Conjunctivitis
Disturbance or loss of smell
Disturbance or loss of taste
Lymphadenopathy
Chest pain
Cough (bloody sputum / haemoptysis)
Cough (with sputum)
Cough (no sputum)
Wheezing
History of fever
Shortness of breath
Headache
Fatigue / Malaise
Muscle aches
Joint pain
Abdominal pain
Vomiting / Nausea
Diarrhoea
Ear pain
Sore throat
Runny nose
phi coefficient
1.0
0.5
0.0
−0.5
−1.0

Figure 4: **Top**: Frequency of comorbidities or other concomitant conditions seen at admission amongst COVID-19 patients. Bars are annotated with a fraction representing the number of patients presenting with this comorbidity over the number of patients for whom presence or absence of this comorbidity was recorded. **Bottom**: The distribution of combinations of the four most common such conditions, amongst all patients for whom these data were recorded. Filled and empty circles below the x-axis indicate the presence or absence of each comorbidity. The "Any other" category contains all remaining conditions in the top plot, and any others recorded as free text by clinical staff. 12.8% of individuals had no comorbidities positively reported on admission. (As data was missing for one or more comorbidities for some patients, this should be regarded as an upper bound).



*Caution when interpreting this result as the sample size is small due to it being a new variable in the dataset.


Proportion of patients
0.3
0.2
0.1
0.0
Any other
Chronic cardiac disease
Hypertension*
Chronic kidney disease
Chronic pulmonary disease
Conditions present at admission

Variables by age

Figure 5: Comorbidities stratified by age group. Boxes show the proportion of individuals with each comorbidity, with error bars showing 95% confidence intervals. The size of each box is proportional to the number of individuals represented. N is the number of individuals included in the plot (this varies between plots due to data completeness).



Figure 6: Symptoms recorded at hospital presentation stratified by age group. Boxes show the proportion of individuals with each symptom, with error bars showing 95% confidence intervals. The size of each box is proportional to the number of individuals represented. N is the number of individuals included in the plot (this varies between plots due to data completeness). **Top**: Left-hand column shows symptoms of fever, cough and shortness of breath, and right-hand column shows the proportions experiencing at least one of these symptoms. **Bottom**: The following symptoms are grouped: upper respiratory is any of runny nose, sore throat or ear pain; constitutional is any of myalgia, joint pain, fatigue or headache.




N = 40503
Upper respiratory symptoms
1.00
0.75
0.50
0.25
0.00
<10
10–
20–
30–
40–
50–
60–
70–
≥ 80
Age group (years)
N = 50847
Confusion
N = 40146
Constitutional symptoms
N = 49946
Nausea or vomiting
N = 49716
Diarrhoea
N = 48184
Abdominal pain

Figure 7: Box and whisker plots for observations at hospital presentation stratified by age group. Outliers are omitted. N is the number of individuals included in the plot (this varies between plots due to data completeness).



Figure 8: Box and whisker plots for laboratory results within 24 hours of hospital presentation stratified by age group. Outliers are omitted. N is the number of individuals included in the plot (this varies between plots due to data completeness). ALT, Alanine transaminase; APTT, Activated partial thromboplastin time; CRP, C-reactive protein; WCC, white cell count




N = 7675
APTT (s)
50
40
30
20
10
0
<10
10–
20–
30–
40–
50–
60–
70–
≥ 80
Age group (years)


N = 16177
Bilirubin (µmol/L)
30
20
10
0
<10
10–
20–
30–
40–
50–
60–
70–
≥ 80
Age group (years)


N = 14701
120
90
60
30
0
<10
10–
20–
30–
40–
50–
60–
70–
≥ 80
Age group (years)

Hospital stays and outcomes

Figure 9: Distribution of length of hospital stay, according to sex. This only includes cases with reported outcomes. The coloured areas indicate the kernel probability density of the observed data and the box plots show the median and interquartile range of the variable of interest. White dots are outliers.



Figure 10: Distribution of length of hospital stay, according to patient age group. This only includes cases with reported outcomes. The coloured areas indicate the kernel probability density of the observed data and the box plots show the median and interquartile range of the variable of interest. White dots are outliers.



Figure 11: Distribution of time (in days) from hospital admission to ICU admission. The figure displays data on only those cases with a reported ICU start date (N=8861).



Figure 12: The distribution of patient status by number of days after admission. Patients with "unknown" status have left the site at the time of report but have unknown outcomes due to missing data. Patients still on site at the time of report appear in the "ongoing care" category for days which are in the future at that time. (For example, a patient admitted 7 days before the date of report and still on site by the date of the report would be categorised as "ongoing care" for days 8 and later.) The black line marks the end of 14 days; due to the cut-off, only a small number of patients appear in the "ongoing care" category left of this line.



Figure 13: Cumulative patient numbers and outcomes by epidemiological week (of 2020) of admission (or, for patients infected in hospital, of symptom onset). The rightmost bar, marked with an asterisk, represents an incomplete week (due to the 14-day cutoff).



Treatment

Figure 14: **Top**: Treatments used. This only includes patients for whom this information was recorded. **Bottom**: The distribution of combinations of antimicrobial treatments and steroids administered during hospital stay, across all patients with completed hospital stay and recorded treatment data. Filled and empty circles below the x-axis indicate treatments that were and were not administered.





*Caution when interpreting this result as the sample size is small due to it being a new variable in the dataset.

Intensive Care and High Dependency Unit Treatments

Figure 15: **Top**: Treatments used amongst patients admitted to the ICU. This only includes patients for whom this information was recorded. **Middle**: The distribution of combinations of treatments administered during ICU/HDU stay. Filled and empty circles below the x-axis indicate treatments that were and were not administered respectively. **Bottom**: Distribution of lengths of stay for patients who were admitted to ICU/HDU: total length of stay for this group and length of stay within intensive care. This only includes cases with reported completed stays. The coloured areas indicate the kernel probability density of the observed data and the box plots show the median and interquartile range of the variable of interest.







*Caution when interpreting this result as the sample size is small due to it being a new variable in the dataset.

Statistical Analysis

Figure 16: Distribution of time from symptom onset to admission. The blue curve is the Gamma distribution fit to the data. The black dashed line indicates the position of the expected mean. The expected mean estimate here differs from the observed mean indicated in the summary text due to the differences in estimation: the mean shown in the figure below is the mean of the fitted Gamma distribution whereas the observed mean (in the summary text) is the arithmetic mean.



Figure 17: Distribution of time from admission to an outcome - either death or recovery (discharge). The blue curve is the Gamma distribution fit to the data. The black dashed line indicates the position of the expected mean. The expected mean differs from the observed mean in that it accounts for unobserved outcomes.



Figure 18: Probabilities of death (red curve) and recovery (green curve) over time. The black line indicates the case fatality ratio (CFR). The method used here considers all cases, irrespective of whether an outcome has been observed. For a completed epidemic, the curves for death and recovery meet. Estimates were derived using a nonparametric Kaplan-Meier–based method proposed by Ghani *et al.* (2005). The point estimate of the CFR is 0.33 (95% CI: 0.32-0.33).



Country Comparisons

Figure 19: Number of sites per country. This reflects all countries contributing data as at 13 July 2020.



Figure 20: Distribution of patients by country. This reflects data on only those countries that are contributing data on patients who satisfy the inclusion criteria outlined in the summary section.



Background

In response to the emergence of novel coronavirus (COVID-19), ISARIC launched a portfolio of resources to accelerate outbreak research and response. These include data collection, analysis and presentation tools which are freely available to all sites which have requested access to these resources. All data collection tools are designed to address the most critical public health questions, have undergone extensive review by international clinical experts, and are free for all to use. Resources are available on the ISARIC website.

The ISARIC-WHO COVID-19 Case Record Form (CRF) enables the collection of standardised clinical data to inform patient management and public health response. These forms should be used to collect data on suspected or confirmed cases of COVID-19. The CRF is available in multiple languages and is now in use across dozens of countries and research consortia, who are contributing data to these reports.

To support researchers to retain control of the data and samples they collect, ISARIC also hosts a data platform, where data can be entered to a web-based REDCap data management system, securely stored, and used to produce regular reports on their sites as above. Data contributors are invited to input on the methods and contents of the reports, and can also contribute to the aggregated data platform which aggregates site-specific data from all other sites across the world who are using this system. For more information, visit the ISARIC website.

All decisions regarding data use are made by the institutions that enter the data. ISARIC keeps contributors informed of any plans and welcomes their input to promote the best science and the interests of patients, institutions and public health authorities. Feedback and suggestions are welcome at ncov@isaric.org.

Methods

Patient details were submitted electronically by participating sites to the ISARIC database. Relevant background and presenting symptoms were recorded on the day of study recruitment. Daily follow-up was then completed until recovery or death. A final form was completed with details of treatments received and outcomes. All categories that represent fewer than five individuals have been suppressed to avoid the potential for identification of participants.

Graphs have been used to represent the age distribution of patients by sex and status (dead, recovered & still in hospital), the prevalence of individual symptoms on admission, comorbidities on admission, the length of hospital stay by sex and age group and the distribution of patient statuses by time since admission. In addition, the number of cases recruited by country and site, as well as the case count by status, has been represented.

Using a non-parametric Kaplan-Meier-based method (Ghani *et al.*, 2005), the case- fatality ratio (CFR) was estimated, as well as probabilities for death and recovery. This method estimates the CFR with the formula $a/(a+b)$, where a and b are the values of the cumulative incidence function for deaths and recoveries respectively, estimated at the last observed time point. In a competing risk context (i.e. where there are multiple endpoints), the cumulative incidence function for an endpoint is equal to the product of the hazard function for that endpoint and the survival function assuming a composite endpoint. It is worth noting that this method assumes that future deaths and recoveries will occur with the same relative probabilities as have been observed so far. Binomial confidence intervals for the CFR were obtained by a normal approximation (See Ghani *et al.*, (2005)).

To obtain estimates for the distributions of time from symptom onset to hospital admission and the time from admission to outcome (death or recovery), Gamma distributions were fitted to the observed data, accounting for unobserved outcomes. Parameters were estimated by a maximum likelihood procedure and confidence intervals for the means and variances were obtained by bootstrap.

All analysis were performed using the R statistical software (R Core Team, 2019).

Caveats

Patient data are collected and uploaded from start of admission, however a complete patient data set is not available until the episode of care is complete. This causes a predictable lag in available data influenced by the duration of admission which is greatest for the sickest patients, and accentuated during the up-phase of the outbreak.

These reports provide regular outputs from the ISARIC COVID-19 database. We urge caution in interpreting unexpected results. We have noted some unexpected results in the report, and are working with sites that submitted data to gain a greater understanding of these.

Summary Tables

Proportions are presented in parentheses. Proportions have been rounded to two decimal places.

Table 1: Patient Characteristics

Description	Value
Size of cohort	60430
By sex	
Male	34422 (0.57)
Female	25899 (0.43)
Unknown	109 (0)
By outcome status	
Dead	17031 (0.28)
Recovered (discharged alive)	34239 (0.57)
Still in hospital	3209 (0.05)
Transferred to another facility	4395 (0.07)
Unknown	1574 (0.03)
By age group	
0-9	429 (0.01)
10-19	315 (0.01)
20-29	1162 (0.02)
30-39	2361 (0.04)
40-49	4243 (0.07)
50-59	7683 (0.13)
60-69	9298 (0.15)
70+	33907 (0.56)
Unknown	1032 (0.02)
Admitted to ICU/HDU?	
Yes	9754 (16)
No/Unknown	50676 (84)

Table 2: Outcome by age and sex. Proportions are calculated using the column total as the denominator.

Variable	**Still in hospital**	**Death**	**Discharge**	**Transferred**	**Unknown**
Age					
0-9	17 (0.01)	8 (0)	376 (0.01)	18 (0)	10 (0.01)
10-19	14 (0)	5 (0)	268 (0.01)	16 (0)	12 (0.01)
20-29	66 (0.02)	23 (0)	1005 (0.03)	23 (0.01)	47 (0.03)
30-39	160 (0.05)	94 (0.01)	1958 (0.06)	83 (0.02)	66 (0.04)
40-49	237 (0.07)	285 (0.02)	3396 (0.1)	220 (0.05)	106 (0.07)
50-59	435 (0.14)	1011 (0.06)	5652 (0.17)	369 (0.08)	218 (0.14)
60-69	549 (0.17)	2125 (0.12)	5745 (0.17)	612 (0.14)	273 (0.17)
70+	1685 (0.53)	13239 (0.78)	15216 (0.44)	2979 (0.68)	795 (0.51)
Sex					
Male	1843 (0.57)	10570 (0.62)	18720 (0.55)	2407 (0.55)	890 (0.57)
Female	1358 (0.42)	6423 (0.38)	15469 (0.45)	1980 (0.45)	679 (0.43)

Table 3: Prevalence of Symptoms

Symptoms	**Present**	**Absent**	**Unknown**
History of fever	37265 (0.62)	19283 (0.32)	3882 (0.06)
Shortness of breath	36050 (0.6)	23560 (0.39)	820 (0.01)
Cough	28653 (0.47)	18294 (0.3)	13483 (0.22)
Fatigue / Malaise	21583 (0.36)	26374 (0.44)	12473 (0.21)
Altered consciousness / confusion	14284 (0.24)	37480 (0.62)	8666 (0.14)
Diarrhoea	9587 (0.16)	41035 (0.68)	9808 (0.16)
Vomiting / Nausea	9559 (0.16)	41285 (0.68)	9586 (0.16)
Muscle aches	8788 (0.15)	36281 (0.6)	15361 (0.25)
Chest pain	6525 (0.11)	42677 (0.71)	11228 (0.19)
Headache	5297 (0.09)	39753 (0.66)	15380 (0.25)
Abdominal pain	5228 (0.09)	43810 (0.72)	11392 (0.19)
Wheezing	3872 (0.06)	43059 (0.71)	13499 (0.22)
Sore throat	3709 (0.06)	40512 (0.67)	16209 (0.27)
Joint pain	3077 (0.05)	40462 (0.67)	16891 (0.28)
Disturbance or loss of taste	1521 (0.03)	20806 (0.34)	38103 (0.63)
Runny nose	1477 (0.02)	42140 (0.7)	16813 (0.28)
Skin ulcers	1134 (0.02)	44983 (0.74)	14313 (0.24)
Disturbance or loss of smell	1021 (0.02)	22006 (0.36)	37403 (0.62)
Bleeding	835 (0.01)	47758 (0.79)	11837 (0.2)
Seizures	759 (0.01)	48457 (0.8)	11214 (0.19)
Skin rash	709 (0.01)	46009 (0.76)	13712 (0.23)
Lymphadenopathy	295 (0)	45746 (0.76)	14389 (0.24)

Table 4: Prevalence of Comorbidities

Comorbidities	Present	Absent	Unknown
Chronic cardiac disease	18044 (0.3)	39020 (0.65)	3366 (0.06)
Hypertension	16074 (0.27)	17108 (0.28)	27248 (0.45)
Chronic kidney disease	9735 (0.16)	46912 (0.78)	3783 (0.06)
Chronic pulmonary disease	9710 (0.16)	47140 (0.78)	3580 (0.06)
Diabetes	9617 (0.16)	45294 (0.75)	5519 (0.09)
Dementia	8876 (0.15)	46756 (0.77)	4798 (0.08)
Asthma	7476 (0.12)	49183 (0.81)	3771 (0.06)
Chronic neurological disorder	6983 (0.12)	49355 (0.82)	4092 (0.07)
Obesity	6432 (0.11)	44234 (0.73)	9764 (0.16)
Rheumatologic disorder	5937 (0.1)	48760 (0.81)	5733 (0.09)
Malignant neoplasm	5693 (0.09)	50521 (0.84)	4216 (0.07)
Smoking	3042 (0.05)	22772 (0.38)	34616 (0.57)
Chronic hematologic disease	2484 (0.04)	52361 (0.87)	5585 (0.09)
Liver disease	1905 (0.03)	53606 (0.89)	4919 (0.08)
Malnutrition	1452 (0.02)	50958 (0.84)	8020 (0.13)
Pregnancy	422 (0.01)	59152 (0.98)	856 (0.01)

Table 5: Prevalence of Treatments

The counts presented for treatments include all cases, not only cases with complete details of treatments (as expressed in the summary).

Treatments	Present	Absent	Unknown
Antibiotic agent	45318 (0.75)	9192 (0.15)	5920 (0.1)
Oxygen therapy	39525 (0.65)	19570 (0.32)	1335 (0.02)
Nasal / mask oxygen therapy	36797 (0.61)	17430 (0.29)	6203 (0.1)
Non-invasive ventilation	9118 (0.15)	49890 (0.83)	1422 (0.02)
High flow oxygen therapy	8896 (0.15)	18047 (0.3)	33487 (0.55)
Corticosteroid agent	8758 (0.14)	44408 (0.73)	7264 (0.12)
Invasive ventilation	5643 (0.09)	50856 (0.84)	3931 (0.07)
Antiviral agent	4552 (0.08)	49042 (0.81)	6836 (0.11)
Inotropes / vasopressors	3446 (0.06)	46373 (0.77)	10611 (0.18)
Prone ventilation	3247 (0.05)	46496 (0.77)	10687 (0.18)
Antifungal agent	2915 (0.05)	50341 (0.83)	7174 (0.12)
Other	1878 (0.03)	22095 (0.37)	36457 (0.6)
Renal replacement therapy	1658 (0.03)	48298 (0.8)	10474 (0.17)
Tracheostomy	1370 (0.02)	48633 (0.8)	10427 (0.17)

Table 6: Key time variables.

SD: Standard deviation; IQR: Interquartile range. Outliers (values greater than 120) were excluded prior to the computation of estimates.

Time (in days)	Mean (observed)	SD (observed)	Median (observed)	IQR (observed)
Length of hospital stay	11.8	11.7	8	11
Symptom onset to admission	7.6	6.1	4	7
Admission to ICU entry	2.9	6.4	1	3
Duration of ICU	12	11.8	8	13.5
Admission to IMV	3.8	7	2	5
Duration of IMV	13.7	10.9	11	13
Admission to NIV	4.2	8.8	2	5
Duration of NIV	2.3	4.8	0	5

Acknowledgements

This report is made possible through the efforts and expertise of the staff collecting data at our partner institutions across the globe, and the ISARIC Team. For a list of partners and team members, please visit https://isaric.tghn.org/covid-19-data-management-hosting-contributors/.

References

Docherty, A.B., E.M. Harrison, C.A. Green, H.E. Hardwick, R. Pius, L. Norman, *et al.*. (2020). Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ*, 369: m1985. doi: 10.1136/bmj.m1985

Ghani, A.C., C.A. Donnelly, D.R. Cox, J.T. Griffin, C. Fraser, T.H. Lam, *et al.* (2005). Methods for Estimating the Case Fatality Ratio for a Novel, Emerging Infectious Disease, *American Journal of Epidemiology*, 162(5): 479 - 486. doi: 10.1093/aje/kwi230.

R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.

RECOVERY (2020, 16 June). Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19

RECOVERY Collaborative Group (2020). Dexamethasone in hospitalized patients with Covid-19 — preliminary report. *New England Journal of Medicine* doi: 10.1056/NEJMoa2021436